Pharmaceuticals & Biotech U.S. Community

I'm not an expert in this field, so I use Copilot to gather information and automate reports. If you notice any inconsistencies that I missed, please let me know so I can revise the model.Read more

Evaxion Biotech is a micro-cap TechBio company punching significantly above its weight class. While the market views it as a small preclinical player, its proprietary AI-Immunology™ platform has already secured a massive validation: a partnership with Merck (MSD).Read more

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Read more

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock!Read more

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more

Eli Lilly’s weight-loss and diabetes medicines keep driving rapid growth, and a new treatment in late-stage testing could make that lead even bigger. The catch is that tougher competition and tighter drug pricing could squeeze profits, so the next round of trial and approval news matters.Read more

High Tide is turning its cannabis stores into something closer to a membership-and-data business, using staff incentives and word of mouth to bring in loyal customers. As that membership base grows, its sales insights become more valuable to growers, which could help it keep winning customers and taking share—if the flywheel keeps spinning.Read more

Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Read more